The United States market has shown robust performance, rising 2.3% over the last week and 35% over the past year, with earnings forecasted to grow by 15% annually. In this thriving environment, a good ...

Stephen Hoge will now oversee vaccine sales at Moderna, per a Bloomberg report. Elsewhere, Intra-Cellular unveiled an ...

Strategic Spinoff Aims to Unlock IP Value and Sharpen Focus on AI Medical Diagnostics. DALLAS, Nov. 06, 2024 (GLOBE NEWSWIRE) ...

CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences: UBS Global Healthcare ...

With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. | With the FDA ...

B. Riley analyst Mayank Mamtani raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $236 from $194 and keeps a Neutral rating on the shares. Madrigal’s Q3 earnings “blowout” print ...

Jefferies analyst Akash Tewari maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a price target ...

The LHM platform integrates seamlessly with Echosens’ FibroScan® technology, offering automated result transfers, biological marker-enhanced exams, and interpretation tools that support more informed, ...

In the ESSENCE trial, semaglutide improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH).

Conshohocken’s Madrigal Pharmaceuticals, saw third-quarter sales soar for its NASH treatment, Rezdiffra, writes John George ...

Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval. Read why I maintain my buy rating ...

A day after Madrigal Pharmaceuticals impressed investors, Novo Nordisk is looking to steal the spotlight. The Danish ...